Plain-English translation of NCT07874451 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a real-world study that tracks how patients with chronic lymphocytic leukemia (a type of blood cancer) respond to treatment with BCL-2 inhibitors. Researchers will gather information from medical records and clinical visits at participating hospitals to understand how well this medication works, what side effects patients experience, and how doctors use it in everyday practice—rather than in controlled research settings.
While this medication has been tested in formal clinical trials, doctors need to understand how it performs in real-world patient populations with different backgrounds and health conditions. This study will help doctors make better treatment decisions and optimize care for people with this type of blood cancer.
You likely qualify if…
You likely don't qualify if…
Participation is non-invasive—you do not receive any new or experimental treatment. Instead, researchers will review your existing medical records and information from your routine clinic visits to understand your disease, how the medication is working for you, and any side effects you may experience. The study will track this information over time as you continue your regular cancer care.
AI-generated summary from trial data · Oct 28, 2026 · Not medical advice
China
Sponsor
The First Affiliated Hospital with Nanjing Medical University
Enrollment target
~300 participants
Started
October 2026
Primary completion
October 2030
Age range
18 Years and older
Last updated on clinicaltrials.gov in October 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Huayuan ZHU
The First Affiliated Hospital with Nanjing Medical University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.